ChemoCentryx, Inc.

ChemoCentryx, Inc. (CCXI), relating to its proposed acquisition by Amgen Inc. Under the terms of the agreement, CCXI shareholders are expected to receive $52.00 in cash per share they own.

To receive more information regarding the investigation of ChemoCentryx, Inc. please fill out the form below.